Phaarmasia Limited (PHRMASI) Fair Value & Analysis
Healthcare · IN · Market cap ₹677M
Fair value as of: Jul 5, 2026
From 14 valuation models · updated 3 days ago
Share price +24.8% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹26.40 – ₹129.20 · fair‑value band ₹109.24 – ₹182.06 · the ₹99.23 price screens below the ₹145.65 fair value. As of Jul 5, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Phaarmasia Limited (PHRMASI) currently trades at ₹99.23, while our model-based Fair Value estimate is ₹145.65 — implying the stock looks roughly 46.8% undervalued today. We read business quality at 73/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.
Over the trailing twelve months, Phaarmasia Limited generated revenue of ₹472M at a net margin of 37.2%. Revenue grew 42.4% year over year. It earns a return on equity of 114.0%. Net debt stands at ₹8.0M. Fundamentals as of Jul 5, 2026
Our scenario range runs from ₹109.24 (bear case) to ₹182.06 (bull case); at ₹99.23, the current price sits below that range. The share trades about 25% below its 52-week high and 282% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -48% fair-value upside — at 47%, PHRMASI screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 5, 2026. TTM = trailing twelve months.
About the company
Phaarmasia Limited manufactures and sells oral contraceptive pills and iron tablets in India. The company offers hormone products, including mifepristone and misoprostaol, desogestrel and ethinyl estradiol, estradiol valerate, levonorgestrel and ethinyl estradiol, medroxyprogesterone acetate, cabergoline, clomiphene citrate, levonorgestrel, progesterone, fluoxymesterone, liothyronine sodium, chlorodehydromethyltestosterone, liothyronine sodium, oxandrolone tablets, testosterone cypionate, methenolone enanthate, drostanolone, testosterone, trenbolone, and stanozolol cypionate injections. It provides herbal products, such as herbal toothpaste, cough and sore throat reliver, and mouth ulcer gel under the Smyle brand name. Phaarmasia Limited was incorporated in 1981 and is based in Hyderabad, India.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Phaarmasia Limited reported revenue of ₹472M in FY2026 versus ₹172M in FY2022, a compound +28.7%/yr. Reported net income was ₹176M in FY2026.
Is PHRMASI fairly valued? → Check now
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 5, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$57.85 | HK$29.84 | -48% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Zoetis Inc Z1TS34 | R$25.93 | R$19.70 | -24% |
| Hansoh Pharmaceutical Group 3692 | HK$29.30 | HK$23.90 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,623 | ₹1,461 | -78% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,464 | ₹1,504 | -66% |
| Cipla Limited CIPLA | ₹1,377 | ₹628.39 | -54% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,089 | ₹841.98 | -23% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,291 | ₹1,053 | -18% |
| PharmaEssentia Corporation 6446 | 934.00 TWD | 365.87 TWD | -61% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Phaarmasia Limited (PHRMASI) undervalued?
What is the fair value of PHRMASI?
What is the quality score of PHRMASI?
What is the revenue of Phaarmasia Limited (PHRMASI)?
What is the net profit margin of PHRMASI?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.